Identification

Name
Ergonovine
Accession Number
DB01253
Type
Small Molecule
Groups
Approved
Description

An ergot alkaloid with uterine and vascular smooth muscle contractile properties.

Structure
Thumb
Synonyms
  • (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
  • [8β(S)]-9,10-didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8-carboxamide
  • 9,10-didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8β(S)-carboxamide
  • 9,10-didehydro-N-(α-(hydroxymethyl)ethyl)-6-methylergoline-8-β-carboxamide
  • D-lysergic acid 1-hydroxymethylethylamide
  • D-lysergic acid-L-propanolamide
  • Ergobasine
  • Ergometrina
  • Ergometrine
  • Ergométrine
  • Ergometrinum
  • Ergonovine
  • Ergotocine
  • Margonovine
  • N-(2-Hydroxy-1-methylethyl)-D-(+)-lysergamide
  • N-(α-(hydroxymethyl)ethyl)-D-lysergamide
Product Ingredients
IngredientUNIICASInChI Key
Ergonovine maleateYMH3D0ZJWV129-51-1YREISLCRUMOYAY-IIPCNOPRSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ergonovine Maleate InjectionSolution0.25 mgIntramuscular; IntravenousMylan Pharmaceuticals1995-12-31Not applicableCanada
Ergonovine Maleate InjectionSolution.25 mgIntramuscular; IntravenousHospira, Inc.1981-12-31Not applicableCanada
Ergonovine Maleate InjectionSolution0.25 mgIntramuscular; IntravenousTeligent Ou2016-02-19Not applicableCanada
Ergonovine Maleate Injection USP, 0.25mg/mlSolution0.25 mgIntramuscular; IntravenousAlveda Pharmaceuticals Inc2010-06-01Not applicableCanada
Ergotrate Maleate Tablet 1572 0.2mgTablet.2 mgOralEli Lilly & Co. Ltd.1939-12-311998-08-04Canada
International/Other Brands
Ergotrate
Categories
UNII
WH41D8433D
CAS number
60-79-7
Weight
Average: 325.4048
Monoisotopic: 325.179026995
Chemical Formula
C19H23N3O2
InChI Key
WVVSZNPYNCNODU-XTQGRXLLSA-N
InChI
InChI=1S/C19H23N3O2/c1-11(10-23)21-19(24)13-6-15-14-4-3-5-16-18(14)12(8-20-16)7-17(15)22(2)9-13/h3-6,8,11,13,17,20,23H,7,9-10H2,1-2H3,(H,21,24)/t11-,13+,17+/m0/s1
IUPAC Name
(4R,7R)-N-[(2S)-1-hydroxypropan-2-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide
SMILES
[H][[email protected]@]12CC3=CNC4=CC=CC(=C34)C1=C[[email protected]](CN2C)C(=O)N[[email protected]@H](C)CO

Pharmacology

Indication

Used to treat postpartum haemorrhage and postabortion haemorrhage in patients with uterine atony.

Structured Indications
Pharmacodynamics

Ergonovine belongs to the group of medicines known as ergot alkaloids. These medicines are usually given to stop excessive bleeding that sometimes occurs after abortion or a baby is delivered. They work by causing the muscle of the uterus to contract.

Mechanism of action

Ergonovine directly stimulates the uterine muscle to increase force and frequency of contractions. With usual doses, these contractions precede periods of relaxation; with larger doses, basal uterine tone is elevated and these relaxation periods will be decreased. Contraction of the uterine wall around bleeding vessels at the placental site produces hemostasis. Ergonovine also induces cervical contractions. The sensitivity of the uterus to the oxytocic effect is much greater toward the end of pregnancy. The oxytocic actions of ergonovine are greater than its vascular effects. Ergonovine, like other ergot alkaloids, produces arterial vasoconstriction by stimulation of alpha-adrenergic and serotonin receptors and inhibition of endothelial-derived relaxation factor release. It is a less potent vasoconstrictor than ergotamine. As a diagnostic aid (coronary vasospasm), ergonovine causes vasoconstriction of coronary arteries.

TargetActionsOrganism
AAlpha-1A adrenergic receptor
agonist
Human
Absorption

Absorption is rapid and complete after oral or intramuscular administration.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination

Thought to be eliminated by non-renal mechanisms (i.e. hepatic metabolism, excretion in feces)

Half life

t1/2 α=10 minutes; t1/2 β=2 hours

Clearance
Not Available
Toxicity

The principal symptoms of overdose are convulsions and gangrene. Other symptoms include bradycardia, confusion, diarrhoea, dizziness, dyspnoea, drowsiness, fast and/or weak pulse, miosis, hypercoagulability, loss of consciousness, nausea and vomiting, numbness and coldness of the extremities, pain in the chest, peripheral vasoconstriction, respiratory depression, rise or fall in blood pressure, severe cramping of the uterus, tachycardia, tingling, and unusual thirst.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Ergonovine can be increased when it is combined with 1,10-Phenanthroline.Experimental
3,4-DichloroisocoumarinThe serum concentration of Ergonovine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Ergonovine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
AcebutololAcebutolol may increase the vasoconstricting activities of Ergonovine.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Aceprometazine.Approved
AcetaminophenThe risk or severity of adverse effects can be increased when Ergonovine is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Acetophenazine.Approved
AdrafinilErgonovine may increase the hypertensive activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Ergonovine.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Aldesleukin.Approved
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Ergonovine.Approved, Investigational
AlogliptinThe serum concentration of Ergonovine can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Ergonovine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlprazolamThe risk or severity of adverse effects can be increased when Ergonovine is combined with Alprazolam.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the vasoconstricting activities of Ergonovine.Approved, Withdrawn
AmbroxolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ambroxol.Approved, Investigational
AmibegronErgonovine may increase the hypertensive activities of Amibegron.Investigational
AmiodaroneThe metabolism of Ergonovine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Amisulpride.Approved, Investigational
AmitrazErgonovine may increase the hypertensive activities of Amitraz.Vet Approved
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Ergonovine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Ergonovine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Amperozide.Experimental
AmprenavirThe serum concentration of Ergonovine can be increased when it is combined with Amprenavir.Approved
AnastrozoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Anastrozole.Approved, Investigational
AnisodamineErgonovine may increase the hypertensive activities of Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Antipyrine.Approved
Antithrombin III humanThe serum concentration of Ergonovine can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Ergonovine can be increased when it is combined with Apixaban.Approved
ApomorphineErgonovine may increase the vasoconstricting activities of Apomorphine.Approved, Investigational
ApraclonidineErgonovine may increase the hypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Ergonovine can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Ergonovine can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineErgonovine may increase the hypertensive activities of Arbutamine.Approved
ArformoterolErgonovine may increase the hypertensive activities of Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Ergonovine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Aripiprazole.Approved, Investigational
ArotinololArotinolol may increase the vasoconstricting activities of Ergonovine.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Arsenic trioxide.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Asenapine.Approved
AstemizoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Ergonovine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Ergonovine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the vasoconstricting activities of Ergonovine.Approved
AtomoxetineThe metabolism of Ergonovine can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Atorvastatin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Azaperone.Investigational, Vet Approved
AzelastineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Azelastine.Approved
AzithromycinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Azithromycin.Approved
BatimastatThe serum concentration of Ergonovine can be increased when it is combined with Batimastat.Experimental
BefunololBefunolol may increase the vasoconstricting activities of Ergonovine.Experimental
BenazeprilThe serum concentration of Ergonovine can be increased when it is combined with Benazepril.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Ergonovine can be increased when it is combined with Benzamidine.Experimental
BetamethasoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Betamethasone.Approved, Vet Approved
BetaxololBetaxolol may increase the vasoconstricting activities of Ergonovine.Approved
BevantololBevantolol may increase the vasoconstricting activities of Ergonovine.Approved
BicalutamideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Bicalutamide.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Ergonovine is combined with Bifeprunox.Investigational
BifonazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Bifonazole.Approved, Investigational
BisoprololBisoprolol may increase the vasoconstricting activities of Ergonovine.Approved
BitolterolErgonovine may increase the hypertensive activities of Bitolterol.Withdrawn
BivalirudinThe serum concentration of Ergonovine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Ergonovine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may increase the vasoconstricting activities of Ergonovine.Approved
BortezomibThe metabolism of Ergonovine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ergonovine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Ergonovine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Ergonovine.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Brexpiprazole.Approved
BrimonidineErgonovine may increase the hypertensive activities of Brimonidine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Ergonovine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Bromperidol.Investigational
BucindololBucindolol may increase the vasoconstricting activities of Ergonovine.Investigational
BufuralolBufuralol may increase the vasoconstricting activities of Ergonovine.Experimental, Investigational
BupranololBupranolol may increase the vasoconstricting activities of Ergonovine.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ergonovine.Approved, Investigational
ButaperazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Butaperazine.Experimental
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Ergonovine.Approved
CaffeineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Caffeine.Approved
CamostatThe serum concentration of Ergonovine can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Ergonovine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Ergonovine can be increased when it is combined with Candoxatrilat.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Capsaicin.Approved
CaptoprilThe serum concentration of Ergonovine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Ergonovine can be increased when combined with Carbamazepine.Approved, Investigational
CarbomycinThe serum concentration of Ergonovine can be increased when it is combined with Carbomycin.Vet Approved
Carboprost TromethamineThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Ergonovine.Approved
CariprazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Cariprazine.Approved
CarteololCarteolol may increase the vasoconstricting activities of Ergonovine.Approved
CarvedilolCarvedilol may increase the vasoconstricting activities of Ergonovine.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Ergonovine is combined with Caspofungin.Approved
CeliprololCeliprolol may increase the vasoconstricting activities of Ergonovine.Approved, Investigational
CeritinibThe serum concentration of Ergonovine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Ergonovine.Withdrawn
ChloramphenicolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Chloramphenicol.Approved, Vet Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Chlorzoxazone.Approved
CholesterolThe serum concentration of Ergonovine can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Ergonovine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Ergonovine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Ergonovine can be increased when it is combined with Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Cilostazol.Approved
CiprofloxacinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ciprofloxacin.Approved, Investigational
CirazolineErgonovine may increase the hypertensive activities of Cirazoline.Experimental
CisaprideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Ergonovine.Approved
ClarithromycinThe metabolism of Ergonovine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ergonovine can be decreased when combined with Clemastine.Approved
ClenbuterolErgonovine may increase the hypertensive activities of Clenbuterol.Approved, Investigational, Vet Approved
ClindamycinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Clindamycin.Approved, Vet Approved
ClofazimineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Clofazimine.Approved, Investigational
ClomifeneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Clomifene.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Ergonovine.Approved, Vet Approved
ClonidineErgonovine may increase the hypertensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Clopenthixol.Experimental
CloranololCloranolol may increase the vasoconstricting activities of Ergonovine.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Ergonovine is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Ergonovine can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Ergonovine can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Ergonovine.Approved
ConivaptanThe serum concentration of Ergonovine can be increased when it is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe risk or severity of adverse effects can be increased when Ergonovine is combined with Cortisone acetate.Approved
CrizotinibThe metabolism of Ergonovine can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Cyamemazine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergonovine.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Ergonovine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Ergonovine.Approved
DabrafenibThe serum concentration of Ergonovine can be decreased when it is combined with Dabrafenib.Approved
DalfopristinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Dalfopristin.Approved
DanazolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Danazol.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Ergonovine.Investigational
DarexabanThe serum concentration of Ergonovine can be increased when it is combined with Darexaban.Investigational
DarunavirThe metabolism of Ergonovine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Ergonovine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Ergonovine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Ergonovine can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Ergonovine can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Ergonovine can be decreased when combined with Delavirdine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Ergonovine.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Desvenlafaxine.Approved
DetomidineErgonovine may increase the hypertensive activities of Detomidine.Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineErgonovine may increase the hypertensive activities of Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Ergonovine.Approved
DextropropoxypheneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DiazepamThe risk or severity of adverse effects can be increased when Ergonovine is combined with Diazepam.Approved, Illicit, Vet Approved
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Diethylstilbestrol.Approved, Investigational
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ergonovine.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Ergonovine.Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Ergonovine.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ergonovine.Approved
DiltiazemThe metabolism of Ergonovine can be decreased when combined with Diltiazem.Approved
Dimethyl sulfoxideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Dimethyl sulfoxide.Approved, Vet Approved
DipivefrinErgonovine may increase the hypertensive activities of Dipivefrin.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Dixyrazine.Experimental
DobutamineErgonovine may increase the hypertensive activities of Dobutamine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Ergonovine is combined with Docetaxel.Approved, Investigational
DolasetronDolasetron may increase the serotonergic activities of Ergonovine.Approved
DopexamineErgonovine may increase the hypertensive activities of Dopexamine.Investigational
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Ergonovine.Approved
DoxorubicinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Doxorubicin.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Ergonovine.Approved, Investigational
DoxycyclineThe metabolism of Ergonovine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Ergonovine can be decreased when combined with Dronedarone.Approved
DroperidolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Droperidol.Approved, Vet Approved
DroxidopaErgonovine may increase the hypertensive activities of Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ergonovine.Approved
EcabetThe serum concentration of Ergonovine can be increased when it is combined with Ecabet.Approved, Investigational
EconazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Econazole.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Ergonovine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Ergonovine is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Ergonovine can be increased when it is combined with Elafin.Investigational
ElbasvirThe risk or severity of adverse effects can be increased when Ergonovine is combined with Elbasvir.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Ergonovine.Approved, Investigational
EnalaprilThe serum concentration of Ergonovine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Ergonovine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Ergonovine can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe risk or severity of adverse effects can be increased when Ergonovine is combined with Enasidenib.Approved
EnzalutamideThe serum concentration of Ergonovine can be decreased when it is combined with Enzalutamide.Approved
EpanololEpanolol may increase the vasoconstricting activities of Ergonovine.Experimental
EphedrineErgonovine may increase the hypertensive activities of Ephedrine.Approved
Epigallocatechin GallateThe serum concentration of Ergonovine can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineErgonovine may increase the hypertensive activities of Epinastine.Approved, Investigational
EpinephrineErgonovine may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Ergonovine.Approved
ErythromycinThe serum concentration of Ergonovine can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Ergonovine.Approved, Investigational
EsmololEsmolol may increase the vasoconstricting activities of Ergonovine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ethanol.Approved
EtilefrineErgonovine may increase the hypertensive activities of Etilefrine.Withdrawn
EtoposideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Ergonovine is combined with Etoricoxib.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Ergonovine.Approved
EzetimibeThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ezetimibe.Approved
FaldaprevirThe serum concentration of Ergonovine can be increased when it is combined with Faldaprevir.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoterolErgonovine may increase the hypertensive activities of Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ergonovine.Approved, Illicit, Investigational, Vet Approved
FluanisoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Ergonovine can be decreased when combined with Fluconazole.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Ergonovine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluphenazine.Approved
FluspirileneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Ergonovine is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Ergonovine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ergonovine.Approved, Investigational
FormoterolErgonovine may increase the hypertensive activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Ergonovine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ergonovine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Ergonovine can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Ergonovine can be increased when combined with Fosphenytoin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Ergonovine.Approved, Investigational
Fusidic AcidThe serum concentration of Ergonovine can be increased when it is combined with Fusidic Acid.Approved
GabexateThe serum concentration of Ergonovine can be increased when it is combined with Gabexate.Investigational
GeldanamycinThe serum concentration of Ergonovine can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemfibrozilThe risk or severity of adverse effects can be increased when Ergonovine is combined with Gemfibrozil.Approved
GlyburideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Glyburide.Approved
Glycerol PhenylbutyrateThe risk or severity of adverse effects can be increased when Ergonovine is combined with Glycerol Phenylbutyrate.Approved
GM6001The serum concentration of Ergonovine can be increased when it is combined with GM6001.Experimental
GranisetronGranisetron may increase the serotonergic activities of Ergonovine.Approved, Investigational
GuanabenzErgonovine may increase the hypertensive activities of Guanabenz.Approved, Investigational
GuanfacineErgonovine may increase the hypertensive activities of Guanfacine.Approved, Investigational
HexoprenalineErgonovine may increase the hypertensive activities of Hexoprenaline.Approved, Withdrawn
HigenamineErgonovine may increase the hypertensive activities of Higenamine.Investigational
HistamineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Histamine.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Hydralazine.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Hydrocortisone.Approved, Vet Approved
IdelalisibThe serum concentration of Ergonovine can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Ergonovine can be increased when it is combined with Idraparinux.Investigational
IfosfamideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ifosfamide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Iloperidone.Approved
ImatinibThe metabolism of Ergonovine can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Ergonovine can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ergonovine.Approved
IndenololIndenolol may increase the vasoconstricting activities of Ergonovine.Withdrawn
IndinavirThe metabolism of Ergonovine can be decreased when combined with Indinavir.Approved
indisulamThe risk or severity of adverse effects can be increased when Ergonovine is combined with indisulam.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Ergonovine is combined with Irbesartan.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Ergonovine is combined with Irinotecan.Approved, Investigational
IsavuconazoniumThe metabolism of Ergonovine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Ergonovine.Approved
IsoetarineErgonovine may increase the hypertensive activities of Isoetarine.Approved
IsoflurophateThe serum concentration of Ergonovine can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe risk or severity of adverse effects can be increased when Ergonovine is combined with Isoniazid.Approved
IsoprenalineErgonovine may increase the hypertensive activities of Isoprenaline.Approved
IsoxsuprineErgonovine may increase the hypertensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Ergonovine can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Ergonovine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ergonovine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Ergonovine can be increased when it is combined with Ixazomib.Approved
JosamycinThe serum concentration of Ergonovine can be increased when it is combined with Josamycin.Approved, Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ketazolam.Approved
KetoconazoleThe serum concentration of Ergonovine can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinThe serum concentration of Ergonovine can be increased when it is combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the vasoconstricting activities of Ergonovine.Approved
LandiololLandiolol may increase the vasoconstricting activities of Ergonovine.Investigational
LansoprazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lansoprazole.Approved, Investigational
LapatinibThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Ergonovine.Approved
LepirudinThe serum concentration of Ergonovine can be increased when it is combined with Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lercanidipine.Approved, Investigational
LetaxabanThe serum concentration of Ergonovine can be increased when it is combined with Letaxaban.Investigational
LevobunololLevobunolol may increase the vasoconstricting activities of Ergonovine.Approved
LevofloxacinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Levofloxacin.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Ergonovine is combined with Levomilnacipran.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Levosalbutamol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Linagliptin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Ergonovine.Approved, Investigational
LisinoprilThe serum concentration of Ergonovine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideErgonovine may increase the vasoconstricting activities of Lisuride.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lithium.Approved
LofexidineErgonovine may increase the hypertensive activities of Lofexidine.Approved, Investigational
LomitapideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lomitapide.Approved
LomustineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lomustine.Approved
LopinavirThe metabolism of Ergonovine can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Loratadine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Ergonovine.Approved
LosartanThe risk or severity of adverse effects can be increased when Ergonovine is combined with Losartan.Approved
LovastatinThe metabolism of Ergonovine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Ergonovine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ergonovine can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Lurasidone.Approved
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Ergonovine.Illicit, Investigational, Withdrawn
ManidipineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ergonovine.Approved
MedetomidineErgonovine may increase the hypertensive activities of Medetomidine.Vet Approved
MefloquineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Mefloquine.Approved
MelagatranThe serum concentration of Ergonovine can be increased when it is combined with Melagatran.Experimental
MelperoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Melperone.Approved, Investigational
MephentermineErgonovine may increase the hypertensive activities of Mephentermine.Approved
MepindololMepindolol may increase the vasoconstricting activities of Ergonovine.Experimental
MequitazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Mesoridazine.Approved, Investigational
MetaraminolErgonovine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Ergonovine.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ergonovine.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Methazolamide.Approved
MethimazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Methimazole.Approved
MethotrimeprazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Methotrimeprazine.Approved
MethoxamineErgonovine may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineErgonovine may increase the hypertensive activities of Methoxyphenamine.Experimental
MethyldopaErgonovine may increase the hypertensive activities of Methyldopa.Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Methylergometrine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Methylprednisolone.Approved, Vet Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Ergonovine.Approved
MetipranololMetipranolol may increase the vasoconstricting activities of Ergonovine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Metoclopramide.Approved, Investigational
MetoprololMetoprolol may increase the vasoconstricting activities of Ergonovine.Approved, Investigational
MetronidazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Metronidazole.Approved
MetyraponeThe risk or severity of adverse effects can be increased when Ergonovine is combined with Metyrapone.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Ergonovine.Experimental
MibefradilThe risk or severity of adverse effects can be increased when Ergonovine is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Ergonovine is combined with Midazolam.Approved, Illicit
MidodrineErgonovine may increase the hypertensive activities of Midodrine.Approved
MifepristoneThe serum concentration of Ergonovine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Ergonovine is combined with Milnacipran.Approved
MirabegronErgonovine may increase the hypertensive activities of Mirabegron.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ergonovine.Approved
MitotaneThe serum concentration of Ergonovine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ergonovine.Approved
ModafinilThe risk or severity of adverse effects can be increased when Ergonovine is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Ergonovine can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Moperone.Experimental
MosapramineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Mosapramine.Experimental
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Ergonovine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NadololNadolol may increase the vasoconstricting activities of Ergonovine.Approved
NafamostatThe serum concentration of Ergonovine can be increased when it is combined with Nafamostat.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Ergonovine.Approved
NaphazolineErgonovine may increase the hypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Ergonovine.Approved, Investigational
NebivololNebivolol may increase the vasoconstricting activities of Ergonovine.Approved, Investigational
NefazodoneThe metabolism of Ergonovine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ergonovine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Ergonovine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ergonovine can be increased when combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Nicardipine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Ergonovine.Approved, Investigational
NicotinamideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Nicotinamide.Approved
NifedipineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Nifedipine.Approved
NilotinibThe metabolism of Ergonovine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Nilvadipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ergonovine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Nitric Oxide.Approved
NitroaspirinThe serum concentration of Ergonovine can be increased when it is combined with Nitroaspirin.Investigational
NitroglycerinErgonovine may decrease the vasodilatory activities of Nitroglycerin.Approved, Investigational
NorepinephrineErgonovine may increase the hypertensive activities of Norepinephrine.Approved
NorfenefrineErgonovine may increase the hypertensive activities of Norfenefrine.Experimental
NorfloxacinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Norfloxacin.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Ergonovine.Approved
NoscapineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Noscapine.Investigational
NylidrinErgonovine may increase the hypertensive activities of Nylidrin.Approved
OctopamineErgonovine may increase the hypertensive activities of Octopamine.Experimental
OlaparibThe metabolism of Ergonovine can be decreased when combined with Olaparib.Approved
OleandomycinThe serum concentration of Ergonovine can be increased when it is combined with Oleandomycin.Vet Approved
OlodaterolErgonovine may increase the hypertensive activities of Olodaterol.Approved
OmapatrilatThe serum concentration of Ergonovine can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the serotonergic activities of Ergonovine.Approved
OrciprenalineErgonovine may increase the hypertensive activities of Orciprenaline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ergonovine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Ergonovine can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Ergonovine can be increased when it is combined with Otamixaban.Investigational
OxprenololOxprenolol may increase the vasoconstricting activities of Ergonovine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Ergonovine is combined with Oxybutynin.Approved, Investigational
OxyfedrineErgonovine may increase the hypertensive activities of Oxyfedrine.Experimental
OxymetazolineErgonovine may increase the hypertensive activities of Oxymetazoline.Approved
OxymetholoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Oxymetholone.Approved, Illicit
OxypertineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Oxypertine.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Ergonovine is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Ergonovine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Ergonovine.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Paramethasone.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ergonovine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Ergonovine.Approved
PenbutololPenbutolol may increase the vasoconstricting activities of Ergonovine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Penfluridol.Experimental
PentobarbitalThe metabolism of Ergonovine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Perazine.Investigational
PergolideErgonovine may increase the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Ergonovine can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Ergonovine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ergonovine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Ergonovine.Approved
PhenobarbitalThe metabolism of Ergonovine can be increased when combined with Phenobarbital.Approved
PhenylephrineErgonovine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineErgonovine may increase the hypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Ergonovine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Ergonovine can be increased when it is combined with Phosphoramidon.Experimental
PiclozotanErgonovine may increase the vasoconstricting activities of Piclozotan.Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Pilocarpine.Approved
PimozideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Pimozide.Approved
PindololPindolol may increase the vasoconstricting activities of Ergonovine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Pipotiazine.Approved, Investigational
PirbuterolErgonovine may increase the hypertensive activities of Pirbuterol.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Ergonovine.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the vasoconstricting activities of Ergonovine.Experimental
PosaconazoleThe serum concentration of Ergonovine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPractolol may increase the vasoconstricting activities of Ergonovine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Ergonovine.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Prednisone.Approved, Vet Approved
PrenalterolErgonovine may increase the hypertensive activities of Prenalterol.Experimental
PrimaquineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Primaquine.Approved
PrimidoneThe metabolism of Ergonovine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Ergonovine can be increased when it is combined with Prinomastat.Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Ergonovine.Approved
ProcaterolErgonovine may increase the hypertensive activities of Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Prochlorperazine.Approved, Vet Approved
ProgesteroneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Progesterone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Ergonovine.Approved
PropericiazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the vasoconstricting activities of Ergonovine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Ergonovine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ergonovine.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Ergonovine.Approved
PRX-00023Ergonovine may increase the vasoconstricting activities of PRX-00023.Investigational
PseudoephedrineErgonovine may increase the hypertensive activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Quetiapine.Approved
QuinaprilThe serum concentration of Ergonovine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Quinidine.Approved
QuinineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Quinine.Approved
QuinupristinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Quinupristin.Approved
RabeprazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Rabeprazole.Approved, Investigational
RacecadotrilThe serum concentration of Ergonovine can be increased when it is combined with Racecadotril.Investigational
RacepinephrineErgonovine may increase the hypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Raclopride.Investigational
RactopamineErgonovine may increase the hypertensive activities of Ractopamine.Vet Approved
RaloxifeneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Raloxifene.Approved, Investigational
RamiprilThe serum concentration of Ergonovine can be increased when it is combined with Ramipril.Approved
RanitidineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Ergonovine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Rasagiline.Approved
RegorafenibThe risk or severity of adverse effects can be increased when Ergonovine is combined with Regorafenib.Approved
RemikirenThe serum concentration of Ergonovine can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Repaglinide.Approved, Investigational
ReproterolErgonovine may increase the hypertensive activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Reserpine.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Resveratrol.Approved, Experimental, Investigational
RifabutinThe metabolism of Ergonovine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ergonovine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ergonovine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Ergonovine.Approved, Investigational
RilmenidineErgonovine may increase the hypertensive activities of Rilmenidine.Investigational
RilpivirineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Rilpivirine.Approved
RimiterolErgonovine may increase the hypertensive activities of Rimiterol.Experimental
RitanserinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ritanserin.Investigational
RitobegronErgonovine may increase the hypertensive activities of Ritobegron.Investigational
RitodrineErgonovine may increase the hypertensive activities of Ritodrine.Approved, Investigational
RivaroxabanThe serum concentration of Ergonovine can be increased when it is combined with Rivaroxaban.Approved
RivastigmineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Rivastigmine.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Ergonovine.Approved
RolitetracyclineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Rolitetracycline.Approved
RomifidineErgonovine may increase the hypertensive activities of Romifidine.Vet Approved
RopiniroleErgonovine may increase the vasoconstricting activities of Ropinirole.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Ergonovine.Approved
RoxithromycinThe serum concentration of Ergonovine can be increased when it is combined with Roxithromycin.Approved, Investigational, Withdrawn
RutinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Rutin.Experimental, Investigational
S-3304The serum concentration of Ergonovine can be increased when it is combined with S-3304.Investigational
SalbutamolErgonovine may increase the hypertensive activities of Salbutamol.Approved, Vet Approved
SalmeterolErgonovine may increase the hypertensive activities of Salmeterol.Approved
SaquinavirThe metabolism of Ergonovine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sarilumab.Approved
SaxagliptinThe serum concentration of Ergonovine can be increased when it is combined with Saxagliptin.Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Ergonovine.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Ergonovine.Approved
SildenafilThe metabolism of Ergonovine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Ergonovine.Approved
SiltuximabThe serum concentration of Ergonovine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ergonovine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ergonovine.Approved
SirolimusThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Ergonovine can be increased when it is combined with Sitagliptin.Approved, Investigational
SitaxentanThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sitaxentan.Approved, Investigational, Withdrawn
SivelestatThe serum concentration of Ergonovine can be increased when it is combined with Sivelestat.Investigational
SolabegronErgonovine may increase the hypertensive activities of Solabegron.Investigational
SolithromycinThe serum concentration of Ergonovine can be increased when it is combined with Solithromycin.Investigational
SorafenibThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sorafenib.Approved, Investigational
SotalolSotalol may increase the vasoconstricting activities of Ergonovine.Approved
SpiraprilThe serum concentration of Ergonovine can be increased when it is combined with Spirapril.Approved
St. John's WortThe serum concentration of Ergonovine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Ergonovine can be increased when it is combined with Stiripentol.Approved
SulfamethoxazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sulfamethoxazole.Approved
SulfanilamideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sulfanilamide.Approved
SulfinpyrazoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Ergonovine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Ergonovine.Approved, Investigational
SynephrineErgonovine may increase the hypertensive activities of Synephrine.Experimental
TacrolimusThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tacrolimus.Approved, Investigational
TadalafilThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tadalafil.Approved, Investigational
TalinololTalinolol may increase the vasoconstricting activities of Ergonovine.Investigational
TamoxifenThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tamoxifen.Approved
TapentadolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Ergonovine.Approved
TelaprevirThe serum concentration of Ergonovine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Ergonovine can be decreased when combined with Telithromycin.Approved
TemocaprilThe serum concentration of Ergonovine can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Ergonovine is combined with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Teniposide.Approved
TerbutalineErgonovine may increase the hypertensive activities of Terbutaline.Approved
TerfenadineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Terfenadine.Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Ergonovine.Experimental
TertatololTertatolol may increase the vasoconstricting activities of Ergonovine.Experimental
TesmilifeneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tesmilifene.Investigational
TestosteroneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Testosterone.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tetracycline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tetrahydropalmatine.Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thioridazine.Approved, Withdrawn
ThiorphanThe serum concentration of Ergonovine can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thiothixene.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tiapride.Approved, Investigational
TicagrelorThe risk or severity of adverse effects can be increased when Ergonovine is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Ergonovine can be decreased when combined with Ticlopidine.Approved
TimololTimolol may increase the vasoconstricting activities of Ergonovine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tioconazole.Approved
TipranavirThe serum concentration of Ergonovine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineErgonovine may increase the hypertensive activities of Tizanidine.Approved
TocilizumabThe serum concentration of Ergonovine can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Ergonovine is combined with Tofisopam.Approved
TopiroxostatThe risk or severity of adverse effects can be increased when Ergonovine is combined with Topiroxostat.Approved, Investigational
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Ergonovine.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ergonovine.Approved, Investigational
TrandolaprilThe serum concentration of Ergonovine can be increased when it is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ergonovine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergonovine.Approved, Investigational
TretoquinolErgonovine may increase the hypertensive activities of Tretoquinol.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Trifluoperazine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Ergonovine.Approved
TroglitazoneThe risk or severity of adverse effects can be increased when Ergonovine is combined with Troglitazone.Investigational, Withdrawn
TroleandomycinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Troleandomycin.Approved
TropisetronTropisetron may increase the serotonergic activities of Ergonovine.Approved, Investigational
TulobuterolErgonovine may increase the hypertensive activities of Tulobuterol.Investigational
TylosinThe serum concentration of Ergonovine can be increased when it is combined with Tylosin.Vet Approved
UbenimexThe serum concentration of Ergonovine can be increased when it is combined with Ubenimex.Experimental, Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Ergonovine.Approved, Experimental
UlinastatinThe serum concentration of Ergonovine can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Ergonovine is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Ergonovine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Ergonovine is combined with Veralipride.Experimental
VerapamilThe metabolism of Ergonovine can be decreased when combined with Verapamil.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Ergonovine.Approved
VildagliptinThe serum concentration of Ergonovine can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Vinblastine.Approved
VincristineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Vincristine.Approved, Investigational
VincristineThe serum concentration of Vincristine can be increased when it is combined with Ergonovine.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe serum concentration of Ergonovine can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ergonovine.Approved
XamoterolErgonovine may increase the hypertensive activities of Xamoterol.Experimental
XimelagatranThe serum concentration of Ergonovine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineErgonovine may increase the hypertensive activities of Xylazine.Vet Approved
YM-178Ergonovine may increase the hypertensive activities of YM-178.Investigational
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Ergonovine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZafirlukastThe risk or severity of adverse effects can be increased when Ergonovine is combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe metabolism of Ergonovine can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe serum concentration of Ergonovine can be increased when it is combined with Zofenopril.Experimental
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ergonovine.Approved, Investigational
ZotepineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Zotepine.Approved, Investigational
ZucapsaicinThe risk or severity of adverse effects can be increased when Ergonovine is combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ergonovine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15383
KEGG Drug
D07905
KEGG Compound
C07543
PubChem Compound
443884
PubChem Substance
46506922
ChemSpider
391970
BindingDB
50390991
ChEBI
4822
ChEMBL
CHEMBL119443
Therapeutic Targets Database
DAP000227
PharmGKB
PA449487
Drugs.com
Drugs.com Drug Page
Wikipedia
Ergonovine
ATC Codes
G02AB03 — Ergometrine
AHFS Codes
  • 76:00.00 — Oxytocics

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentPost Partum Hemorrhage2
Not AvailableCompletedTreatmentPostpartum Hemorrhage2
Not AvailableRecruitingTreatmentPostpartum Hemorrhage1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
SolutionIntramuscular; Intravenous.25 mg
SolutionIntramuscular; Intravenous0.25 mg
TabletOral.2 mg
Prices
Unit descriptionCostUnit
Ergonovine maleate 100% powder676.9USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)162 °CPhysProp
water solubility2.68 mg/mL at 25 °CMEYLAN,WM et al. (1996)
logP0.9Not Available
pKa6.8MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.321 mg/mLALOGPS
logP1.53ALOGPS
logP1.07ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)15ChemAxon
pKa (Strongest Basic)7.93ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area68.36 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity95.05 m3·mol-1ChemAxon
Polarizability36.54 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9967
Blood Brain Barrier+0.6971
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8385
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.7295
CYP450 2C9 substrateNon-substrate0.8097
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.6814
CYP450 1A2 substrateNon-inhibitor0.7284
CYP450 2C9 inhibitorNon-inhibitor0.9116
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9228
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9236
Ames testNon AMES toxic0.5743
CarcinogenicityNon-carcinogens0.9353
BiodegradationNot ready biodegradable0.8714
Rat acute toxicity3.3967 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.954
hERG inhibition (predictor II)Inhibitor0.5624
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as lysergamides. These are amides of Lysergic acids.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Ergoline and derivatives
Sub Class
Lysergic acids and derivatives
Direct Parent
Lysergamides
Alternative Parents
Indoloquinolines / Benzoquinolines / Quinoline-3-carboxamides / Pyrroloquinolines / 3-alkylindoles / Isoindoles and derivatives / Aralkylamines / Benzenoids / Heteroaromatic compounds / Pyrroles
show 9 more
Substituents
Lysergic acid amide / Indoloquinoline / Benzoquinoline / Pyrroloquinoline / Quinoline-3-carboxamide / Quinoline / 3-alkylindole / Indole / Indole or derivatives / Isoindole or derivatives
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, organic heterotetracyclic compound, monocarboxylic acid amide, secondary amino compound, ergot alkaloid, primary alcohol (CHEBI:4822) / Indole alkaloids (C07543)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Gibson A, Carvajal A: Agonist profile of ergometrine (ergonovine) on a population of postsynaptic alpha-adrenoceptors. J Pharm Pharmacol. 1988 Feb;40(2):137-9. [PubMed:2897449]
  2. Zhu F, Han B, Kumar P, Liu X, Ma X, Wei X, Huang L, Guo Y, Han L, Zheng C, Chen Y: Update of TTD: Therapeutic Target Database. Nucleic Acids Res. 2010 Jan;38(Database issue):D787-91. doi: 10.1093/nar/gkp1014. Epub 2009 Nov 20. [PubMed:19933260]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Moubarak AS, Rosenkrans CF Jr, Johnson ZB: Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine. Vet Hum Toxicol. 2003 Feb;45(1):6-9. [PubMed:12583687]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113]
  2. Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267]

Drug created on April 04, 2007 16:45 / Updated on November 19, 2017 20:34